Russian-school peptides and a Cochrane-level negative.

The Russian nootropic peptides sit in a strange evidence pocket. They've been studied in real human trials — in some cases more than entire categories of better-known Western peptides. But the trials are mostly Russian-language, older, smaller, and well below Western RCT (randomized controlled trial) standards. We'll walk through each one honestly.

Two histories collide here. The first is the Russian short-peptide tradition. It dates to the 1970s Khavinson school in St. Petersburg and the parallel work at the Institute of Molecular Genetics in Moscow. That research culture produced small, single-center clinical work on neuropeptides for stroke recovery, anxiety, cognitive decline, and aging. The trials shaped clinical practice in Russia. Two products came out of it as approved drugs (Selanc and Sema), still dispensed there today.

The second is Western RCT methodology. The multi-center, double-blind, placebo-controlled, pre-registered, statistically-powered, English-peer-reviewed standard that defines FDA and EMA approval. The Russian neuropeptide literature hasn't met that bar. It produced consistent positive single-center signals and an active Russian clinical practice. It didn't produce the Phase III programs that translate to Western approval.

The honest framing: both histories are real. The Russian data isn't fake. It's also not equivalent to a Cochrane-level RCT review. We'll frame each of the four molecules, then drop the evidence-tier callout that separates the Russian-pharmacy-approved compounds from the more speculative Khavinson-school peptides.

Selank: the anxiolytic tuftsin analog

Selank is a synthetic seven-amino-acid peptide. It's a stabilized analog of tuftsin, a natural immune-system signaling peptide. The sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro, with an N-terminal acetyl group that protects it from breakdown.

The molecule was developed at the Institute of Molecular Genetics in Moscow in the 1980s. It's currently dispensed in Russia as an intranasal anti-anxiety drug under the trade name Selanc.

The Russian clinical pattern is consistent. 10+ Russian RCTs and open-label studies (typically n=20–60) in study participants with generalized anxiety disorder, adjustment disorder, and asthenia (chronic fatigue + weakness) have reported significant anxiety-score reductions on validated scales.

The proposed mechanism is multifactorial: modulation of serotonin and GABA pathways, anti-inflammatory cytokine effects (notably lower IL-6), and stabilization of the stress-response axis (HPA). All of it without the sedation, dependence, or withdrawal that come with benzodiazepines.

What the Russian literature doesn't have: a Western Phase III RCT with hundreds of participants, a pre-registered primary outcome, and peer review in a high-impact English journal. The largest published Selank trial is around 200 participants. Several of the receptor-binding claims (especially the GABA story) rest on a small handful of preclinical studies. Read the full Selank guide →

Semax

Heptapeptide ACTH 4-10 analog N-acetylated

The same compound cited across the Russian stroke-recovery and cognitive-resilience studies. Lab-verified identity and purity.

View Semax

Semax: the ACTH 4-10 analog for stroke and cognition

Semax is a synthetic seven-amino-acid peptide built from a fragment of ACTH (adrenocorticotropic hormone). The sequence: Met-Glu-His-Phe-Pro-Gly-Pro. It came from the same Russian institute as Selank and is dispensed in Russia as Sema for stroke recovery, cognitive support, and optic-nerve disorders.

The stroke-recovery data

This is the most-cited Russian application. Multiple post-stroke recovery RCTs have reported meaningful improvements in neurological recovery scores. The largest trial enrolled about 300 study participants across multiple Russian centers and reported improvement on the NIHSS stroke scale at 30 days versus placebo.

The proposed mechanism: upregulation of BDNF and NGF (two brain-cell-survival growth factors), modulation of serotonin and dopamine pathways, and neuroprotection in stroke models.

The honest caveats

The largest Semax trials haven't been replicated by Western groups. Several of the Russian stroke-recovery studies were open-label or single-blind, and the primary outcomes varied between trials. That's below current Cochrane standards.

The 2020 Cochrane review of pharmacological interventions for acute ischemic stroke didn't include Semax in its primary analysis. The available trials didn't meet inclusion criteria. The cognitive-resilience and nootropic claims rest on an even smaller, weaker subset of the same Russian literature. Read the full Semax guide →

Epithalon: the Khavinson school's anti-aging tetrapeptide

Epithalon (also Epitalon) is a synthetic four-amino-acid peptide derived from epithalamin, a pineal-gland extract. Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology characterized it starting in the 1970s. Sequence: Ala-Glu-Asp-Gly (AEDG).

It's the flagship of the Khavinson school's broader "peptide bioregulator" program — the idea that short peptides derived from organ extracts produce tissue-specific regulatory effects.

The Russian preclinical literature is extensive. Khavinson and colleagues have reported telomerase activation in human cells, melatonin enhancement in the pineal gland, and broad anti-aging effects across 30+ years of rodent models. The lab has consistently reported lifespan extension in rodents and improvements in cardiovascular and immune biomarkers in older humans.

Honest reading: the Khavinson program is real and internally consistent. It hasn't been replicated, validated, or peer-reviewed at the level needed to count as established science in Western literature. Read the full Epithalon guide →

DSIP: the older Russian-adjacent sleep peptide

Delta Sleep-Inducing Peptide (DSIP) is a nine-amino-acid peptide (sequence WAGGDASGE). A Swiss group — not a Russian one — first isolated it in 1977 from the cerebral blood of sleeping rabbits.

It belongs in this category because most of the later clinical work was done by Russian and Eastern European groups, and its consumer-market positioning today flows from that lineage.

The clinical literature is small and old. A handful of 1980s and early-1990s studies (about 80 cumulative participants) investigated DSIP for chronic pain, sleep disorders, opioid withdrawal, and stress resilience. Results were inconsistent.

The proposed mechanism — modulation of slow-wave (deep) sleep and the stress-response axis — has never been characterized at the receptor level. That's unusual for a peptide that's been studied for nearly five decades.

DSIP is the evidence-thinnest of the four. Selank and Semax have real (if methodologically older) clinical work. Epithalon has a large single-group preclinical program. DSIP has only a sparse, older, mixed-results clinical literature. Read the full DSIP guide →

Where the Russian school sits in 2026

How this category sits against the broader peptide-research landscape: the Russian school produced a real, consistent body of clinical work on Selank and Semax that exceeds the human evidence base for many better-known Western peptides (BPC-157, TB-500, MOTS-c, the growth-hormone-releasing peptides). It hasn't produced a Cochrane-level multi-center Phase III program for any of them. Epithalon and DSIP sit further below that bar.

The practical reading: the question "is there real human data?" frames the category incompletely. The more relevant questions are whether the human data meets Western regulatory standards (it does not) and whether it is consistent enough to have informed clinical practice in Russia (it has, for Selank and Semax in specific indications). The marketing leap that turns Russian anxiety-trial data into a general nootropic claim, or Khavinson's preclinical work into a longevity therapy, significantly outpaces what the source literature actually supports.

Selank

11 mg ≥99% pure Lyophilized

A synthetic N-acetylated heptapeptide tuftsin analog — the same compound dispensed in Russia as Selanc and studied across the cited Russian clinical trials. Research-grade reference compound. COA available with each lot.

Learn more

Why hasn't Western RCT methodology picked up these peptides?

Three structural reasons explain the gap.

First, the commercial incentive isn't there. The Russian molecules are off-patent or have only Russian protection. No Western pharmaceutical company has a financial reason to fund a $50–100M Phase III program for an unprotectable molecule.

Second, the regulatory translation is hard. Russian state-clinical registrations aren't directly accepted by the FDA or EMA. A Western Phase III would essentially mean starting development from scratch despite the existing Russian data.

Third, the indication boundaries are fuzzy. The Russian indications (asthenia, post-stroke recovery, cognitive resilience) overlap with conditions Western regulators evaluate differently. The trial endpoints used in Russia don't always map cleanly to Western primary-outcome standards.

This isn't the same as saying the molecules are pseudoscience or that the Russian data is fabricated. It's saying the development pipeline that would convert Russian clinical practice into Western FDA-approved drugs hasn't been funded. Whether it ever will be is open. It depends more on commercial incentives than on the underlying biology.

Evaluating this category against the evidence

Researchers and reviewers examining the Russian nootropic peptide literature typically focus on a consistent set of methodological questions:

• Selank/Semax versus Epithalon/DSIP. Selank and Semax have active Russian clinical practice. Epithalon and DSIP are more speculative. The evidence tiers differ enormously.
• Indication specificity. Selank for generalized anxiety has the most Russian clinical evidence. Semax for stroke recovery has the second-most. The "general nootropic" framing for either sits downstream of the actual trial data.
• Defined endpoints. The Russian trials used specific validated scales (HAM-A for anxiety, NIHSS for stroke). Studies without a pre-defined primary endpoint are methodologically harder to interpret.
• Administration route in the source literature. The Russian clinical studies investigated intranasal administration for Selank and Semax. Alternative routes represent modifications with distinct pharmacokinetic profiles not characterized in the published literature.
• Reference compound purity. Supply-chain purity is a material variable for research validity, particularly for compounds with subtle biological effects at low concentrations.